Insiders Seeing Green With NVAX At New 52-Week High

In trading on Monday, shares of Novavax, Inc. ( NVAX) touched a new 52-week high of $10.00/share. That's a 155.10% rise, or $6.08 per share from the 52-week low of $3.92 set back on 10/02/2014. That means at today's intraday high, any investor who purchased NVAX stock any time over the past 52 weeks has an unrealized gain, including company insiders.

Over the past six months, insiders have been scooping up shares, and those bets are now paying off handsomely. As summarized by the table below, NVAX has seen 7 different instances of insiders buying over the trailing six month period.

START SLIDESHOW:
Ten Bargains You Can Buy Cheaper Than The Insiders Did »

Purchased Insider Title Shares Price/Share Value
01/31/2015 John Trizzino SVP, Commercial Operations 6,611 $3.63 $23,997.93
01/31/2015 John A. Herrmann III SVP, General Counsel 9,869 $2.28 $22,501.32
01/31/2015 Timothy Jon Hahn SVP, Manufacturing 9,329 $2.28 $21,270.12
01/31/2015 Russell P. Wilson SVP, Business Development 5,050 $2.28 $11,514.00
01/31/2015 Gregory M. Glenn SVP, Research and Development 866 $2.28 $1,974.48
01/31/2015 Barclay A. Phillips SVP, Chief Financial Officer 8,388 $2.28 $19,124.64
01/31/2015 Stanley C. Erck CEO and President 6,122 $2.28 $13,958.16
01/31/2015 Russell P. Wilson SVP, Business Development 5,050 $2.28 $11,514.00
01/31/2015 Gregory M. Glenn SVP, Research and Development 866 $2.28 $1,974.48
01/31/2015 Barclay A. Phillips SVP, Chief Financial Officer 8,388 $2.28 $19,124.64
01/31/2015 Stanley C. Erck CEO and President 6,122 $2.28 $13,958.16

The chart below shows where NVAX has traded over the past year, with the 50-day and 200-day moving averages included.

Novavax, Inc. Moving Averages Chart

In afternoon trading on Monday, NVAX shares are changing hands at $9.82/share, slightly below the new 52-week high.

If you liked this article you might like

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Biotech Movers: Alexion, Arena, Novavax

Biotech Movers: Alexion, Arena, Novavax

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering